Media Inquiries: For all MAVA media inquiries, please contact Audrey Chang at 202-295-8779 or email audrey.chang@harbourgrp.com.
Check back regularly for news, coverage, and announcements about MAVA.
Epizyme, a Cambridge-based biopharmaceutical company, has filed with the Securities and Exchange Commission for its initial public offering of stock to raise an estimated $69 million.
Few know LivingSocial like Don Rainey. The Grotech general partner's involvement with the D.C. daily deal giant predates the daily deal itself. Rainey has sat on LivingSocial's board long enough to see it reach the peak of press adulation, only to be hammered by a seemingly endless string of bad news.
Picture yourself out in a neighborhood “driving for dollars”. You come across a potential real estate investment opportunity and you want to learn more about the property.
IDA Ireland today announced the planned creation of 95 new jobs by two client companies in the software sector in the next 3 years.
Search, social and mobile advertising player Marin Software Inc is to create 35 new jobs in Dublin over the next three years.
Major house price declines have eased in Ireland in 2012, thanks to the increasing demand from tech companies like Google, Linkedin and Facebook, which have set up offices and headquarters in the country.
D.C. ranks No. 1 for startups per million residents, according to a list from Fast Company.
Epizyme, a Massachusetts-based biopharmaceutical firm backed by Chevy Chase-based New Enterprise Associates (NEA), has filed with the Securities and Exchange Commission (SEC) to raise up to $69 million in its initial public offering.
MC10, a Cambridge-based developer of “conformable” electronics that stretch, bend and twist, has raised $18 million in its third round of venture capital, the company announced on Thursday.
A pair of Vienna-based venture capital firms, Valhalla Partners and Grotech Ventures, have co-led a new $3.8 million round of funding for Pennsylvania-based Zonoff, developer of a connected home software platform.